Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | NOP53 | Human | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NOP53 mRNA | CTD | PMID:22079256 | NOP53 | Human | 1,2-dimethylhydrazine | increases expression | ISO | Nop53 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in increased expression of GLTSCR2 mRNA | CTD | PMID:22206623 | NOP53 | Human | 17alpha-ethynylestradiol | multiple interactions | ISO | Nop53 (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of NOP53 mRNA | CTD | PMID:17942748 | NOP53 | Human | 17beta-estradiol | affects expression | EXP | | 6480464 | Estradiol affects the expression of NOP53 mRNA | CTD | PMID:22574217 | NOP53 | Human | 17beta-estradiol | decreases expression | EXP | | 6480464 | Estradiol results in decreased expression of NOP53 mRNA | CTD | PMID:31614463 | NOP53 | Human | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Nop53 (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of NOP53 mRNA | CTD | PMID:17942748 | NOP53 | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Nop53 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of NOP53 mRNA | CTD | PMID:33387578 | NOP53 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Nop53 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of NOP53 mRNA | CTD | PMID:34747641 | NOP53 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of NOP53 mRNA | CTD | PMID:22574217 | NOP53 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Nop53 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of NOP53 mRNA | CTD | PMID:21215274 | NOP53 | Human | 2,3,7,8-Tetrachlorodibenzofuran | increases expression | ISO | Nop53 (Rattus norvegicus) | 6480464 | 2 more ... | CTD | PMID:32109520 | NOP53 | Human | 3,4-methylenedioxymethamphetamine | increases expression | ISO | Nop53 (Mus musculus) | 6480464 | N-Methyl-3 and 4-methylenedioxyamphetamine results in increased expression of NOP53 mRNA | CTD | PMID:20188158 | NOP53 | Human | 4,4'-diaminodiphenylmethane | increases expression | ISO | Nop53 (Mus musculus) | 6480464 | 4 and 4'-diaminodiphenylmethane results in increased expression of NOP53 mRNA | CTD | PMID:18648102 | NOP53 | Human | 4,4'-sulfonyldiphenol | increases expression | ISO | Nop53 (Mus musculus) | 6480464 | bisphenol S results in increased expression of NOP53 mRNA | CTD | PMID:31881267 | NOP53 | Human | acrylamide | increases expression | ISO | Nop53 (Mus musculus) | 6480464 | Acrylamide results in increased expression of NOP53 mRNA | CTD | PMID:30807115 | NOP53 | Human | aflatoxin B1 | decreases expression | EXP | | 6480464 | Aflatoxin B1 results in decreased expression of NOP53 mRNA | CTD | PMID:27153756 | NOP53 | Human | all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of NOP53 mRNA | CTD | PMID:23724009 | NOP53 | Human | aristolochic acid A | multiple interactions | ISO | Nop53 (Rattus norvegicus) | 6480464 | [aristolochic acid I co-treated with aristolochic acid II] results in decreased expression of NOP53 mRNA | CTD | PMID:23912714 | NOP53 | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of NOP53 protein | CTD | PMID:33212167 | NOP53 | Human | bisphenol A | increases expression | ISO | Nop53 (Mus musculus) | 6480464 | bisphenol A results in increased expression of NOP53 mRNA | CTD | PMID:26063408 and PMID:32156529 | NOP53 | Human | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of NOP53 protein | CTD | PMID:33376534 | NOP53 | Human | bisphenol A | increases expression | ISO | Nop53 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of NOP53 mRNA | CTD | PMID:25181051 more ... | NOP53 | Human | buspirone | increases expression | ISO | Nop53 (Rattus norvegicus) | 6480464 | Buspirone results in increased expression of NOP53 mRNA | CTD | PMID:24136188 | NOP53 | Human | caffeine | decreases phosphorylation | EXP | | 6480464 | Caffeine results in decreased phosphorylation of NOP53 protein | CTD | PMID:35688186 | NOP53 | Human | calcium silicate | increases expression | ISO | Nop53 (Mus musculus) | 6480464 | calcium silicate results in increased expression of NOP53 mRNA | CTD | PMID:29279043 | NOP53 | Human | carbon nanotube | increases expression | ISO | Nop53 (Mus musculus) | 6480464 | Nanotubes and Carbon results in increased expression of NOP53 mRNA | CTD | PMID:25620056 | NOP53 | Human | chloropicrin | increases expression | EXP | | 6480464 | chloropicrin results in increased expression of NOP53 mRNA | CTD | PMID:26352163 | NOP53 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of NOP53 mRNA | CTD | PMID:27392435 | NOP53 | Human | clozapine | affects expression | ISO | Nop53 (Mus musculus) | 6480464 | Clozapine affects the expression of NOP53 mRNA | CTD | PMID:14647396 | NOP53 | Human | cobalt dichloride | increases expression | EXP | | 6480464 | cobaltous chloride results in increased expression of NOP53 mRNA | CTD | PMID:19376846 | NOP53 | Human | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of NOP53 mRNA | CTD | PMID:20106945 and PMID:27989131 | NOP53 | Human | doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of NOP53 mRNA | CTD | PMID:29803840 | NOP53 | Human | enzyme inhibitor | multiple interactions | EXP | | 6480464 | [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of NOP53 protein | CTD | PMID:23301498 | NOP53 | Human | ethanol | affects splicing | ISO | Nop53 (Mus musculus) | 6480464 | Ethanol affects the splicing of NOP53 mRNA | CTD | PMID:30319688 | NOP53 | Human | fipronil | increases expression | ISO | Nop53 (Rattus norvegicus) | 6480464 | fipronil results in increased expression of NOP53 mRNA | CTD | PMID:34044035 | NOP53 | Human | glafenine | decreases expression | ISO | Nop53 (Rattus norvegicus) | 6480464 | Glafenine results in decreased expression of NOP53 mRNA | CTD | PMID:24136188 | NOP53 | Human | haloperidol | increases expression | ISO | Nop53 (Mus musculus) | 6480464 | Haloperidol results in increased expression of NOP53 mRNA | CTD | PMID:14647396 | NOP53 | Human | ivermectin | decreases expression | EXP | | 6480464 | Ivermectin results in decreased expression of NOP53 protein | CTD | PMID:32959892 | NOP53 | Human | lead(0) | affects expression | EXP | | 6480464 | Lead affects the expression of NOP53 mRNA | CTD | PMID:28903495 | NOP53 | Human | paracetamol | affects expression | ISO | Nop53 (Mus musculus) | 6480464 | Acetaminophen affects the expression of NOP53 mRNA | CTD | PMID:17562736 | NOP53 | Human | paracetamol | decreases expression | ISO | Nop53 (Rattus norvegicus) | 6480464 | Acetaminophen results in decreased expression of NOP53 mRNA | CTD | PMID:33387578 | NOP53 | Human | perfluorohexanesulfonic acid | decreases expression | EXP | | 6480464 | perfluorohexanesulfonic acid results in decreased expression of GLTSCR2 mRNA | CTD | PMID:25812627 | NOP53 | Human | perfluorononanoic acid | decreases expression | EXP | | 6480464 | perfluoro-n-nonanoic acid results in decreased expression of GLTSCR2 mRNA | CTD | PMID:25812627 | NOP53 | Human | perfluorooctane-1-sulfonic acid | decreases expression | EXP | | 6480464 | perfluorooctane sulfonic acid results in decreased expression of GLTSCR2 mRNA | CTD | PMID:25812627 | NOP53 | Human | perfluorooctanoic acid | decreases expression | EXP | | 6480464 | perfluorooctanoic acid results in decreased expression of GLTSCR2 mRNA | CTD | PMID:25812627 | NOP53 | Human | phenethyl isothiocyanate | decreases expression | ISO | Nop53 (Rattus norvegicus) | 6480464 | phenethyl isothiocyanate results in decreased expression of NOP53 mRNA | CTD | PMID:17616710 | NOP53 | Human | potassium chromate | increases expression | EXP | | 6480464 | potassium chromate(VI) results in increased expression of NOP53 mRNA | CTD | PMID:22079256 | NOP53 | Human | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NOP53 mRNA | CTD | PMID:22079256 | NOP53 | Human | propiconazole | decreases expression | ISO | Nop53 (Mus musculus) | 6480464 | propiconazole results in decreased expression of NOP53 mRNA | CTD | PMID:21278054 | NOP53 | Human | resveratrol | multiple interactions | EXP | | 6480464 | [Plant Extracts co-treated with Resveratrol] results in increased expression of NOP53 mRNA | CTD | PMID:23557933 | NOP53 | Human | rotenone | increases expression | ISO | Nop53 (Rattus norvegicus) | 6480464 | Rotenone results in increased expression of GLTSCR2 mRNA | CTD | PMID:28374803 | NOP53 | Human | sodium arsenite | increases expression | EXP | | 6480464 | sodium arsenite results in increased expression of NOP53 mRNA | CTD | PMID:38568856 | NOP53 | Human | temozolomide | increases expression | EXP | | 6480464 | Temozolomide results in increased expression of NOP53 mRNA | CTD | PMID:31758290 | NOP53 | Human | tetrachloroethene | increases expression | ISO | Nop53 (Mus musculus) | 6480464 | Tetrachloroethylene results in increased expression of NOP53 mRNA | CTD | PMID:28973375 | NOP53 | Human | thimerosal | decreases expression | EXP | | 6480464 | Thimerosal results in decreased expression of NOP53 mRNA | CTD | PMID:27188386 | NOP53 | Human | thiram | increases expression | EXP | | 6480464 | Thiram results in increased expression of NOP53 mRNA | CTD | PMID:38568856 | NOP53 | Human | titanium dioxide | affects expression | ISO | Nop53 (Mus musculus) | 6480464 | titanium dioxide affects the expression of NOP53 mRNA | CTD | PMID:23557971 | NOP53 | Human | tunicamycin | increases expression | EXP | | 6480464 | Tunicamycin results in increased expression of NOP53 mRNA | CTD | PMID:29453283 | NOP53 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of NOP53 mRNA | CTD | PMID:23179753 and PMID:28001369 | NOP53 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of NOP53 mRNA | CTD | PMID:25979313 | |